– USA, NC – United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the election of Jan Malcolm to its Board of Directors effective on June 26, 2024, filling the seat held by Professor Katherine Klein, who did not stand for re-election at the 2024 AGM.
About Jan Malcolm
Jan Malcolm is an accomplished leader in health policy, public health, and healthcare finance and delivery. She has demonstrated a career-long dedication to improving the health of the public and the care of complex populations. In recognition of her many accomplishments, in February 2024 the American Medical Association (AMA) presented Ms. Malcolm with the AMA Award for Outstanding Government Service.
Jan Malcolm was twice Minnesota’s Commissioner of Health under three governors representing two political parties from 1999 to 2003 and from 2018 to 2023. During her tenure, Ms. Malcolm earned a national reputation as one of the first healthcare leaders to highlight health disparities and the impact of social determinants of health. As Health Commissioner during the COVID-19 pandemic, she also played an instrumental and visible role in educating the public, creating dynamic and user-friendly systems for sharing COVID-19 data with the people of Minnesota, and rapidly expanding testing capacity. Ms. Malcolm also has significant healthcare operational experience, having served as a vice president of the Allina Health System, and as CEO of the Courage Center, a leading provider of rehabilitation and health services for people with disabilities.
“It’s an honor to support United Therapeutics’ unique mission to address critical unmet medical needs of patients,” said Ms. Jan Malcolm. “I look forward to working with the Board and senior management, which collectively bring together the skills needed to make a difference for patients with rare lung diseases and other end-stage organ diseases.”
Jan Malcolm received a bachelor’s degree in philosophy and psychology from Dartmouth College.
About United Therapeutics
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
